Explore
Validate
Learn28076-1-AP
antibody from Proteintech Group
Targeting: CD274
B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [153]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 28076-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- PD-L1/CD274 (C-terminal) antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated PD-L1/CD274 (C-terminal) antibody (Cat. #28076-1-AP) is a rabbit polyclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Exosomal lncRNA FENDRR Orchestrates Immune Remodelling and Ferroptosis in the Comorbidity of Lung Cancer and Type 1 Myocardial Infarction.
Globulol from Alpinia oxyphylla Miq. Enhances the pharmacological effects of anti-PD-1 drugs in combination by reducing PD-L1 expression in hepatocellular carcinoma.
Targeting CPS1 attenuates lung cancer metastasis by regulating EMT through an epigenetic mechanism.
Targeting the ANXA2-CD63-exosomal PD-L1 axis in hepatocellular carcinoma: A novel mechanism of immune evasion and its implications for precision immunotherapy.
Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative breast cancer.
Tudor domain-containing protein 9-targeting siRNA nanoparticles alleviate Pseudomonas aeruginosa lung injury in preclinical models by promoting neutrophil cuproptosis.
Kukoamine B Inhibits EMT in Lung Adenocarcinoma Cells by Regulating Intracellular PD-L1-Mediated p65 Nuclear Translocation.
Engineered Bacteria-Driven Biohybrid Microrobots Potentiate IL-2 Immunotherapy by Evoking Pyroptosis.
Pyroptosis-Inducing Engineered Microparticles for Cancer Immunotherapy.
Integrin β4 drives immune evasion and therapeutic resistance to PD-1 blockade in bladder cancer via MEK/ERK signaling.
Isoimperatorin inhibits cell proliferation and induces apoptosis via regulating PI3K/AKT pathway in acute lymphoblastic leukemia.
The active compound quercetin from Polygonum cuspidatum targets COL3A1 to enhance CD8⁺ T cell cytotoxicity in gastric cancer.
Venlafaxine suppressed PD-L1 expression through oxidative stress and improved anti-tumour immune responses in melanoma mice.
Anti-Protein-Adsorption Nano-Proteolysis Targeting Chimeras as a Potent Platform for Efficient Programmed Cell Death Ligand 1 Degradation.
An effective tumor-inhibiting siRNA delivery platform.
Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.
H3K27ac-induced IFITM3 promotes progression of TNBC and resistance to anti-PD-1/PD-L1 therapy via the TNF-α/NF-κB/PD-L1 axis.
Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer.
Interferon Regulatory Factor 4 Recruits Immature B Cells to Signal Tertiary Lymphoid Structure Immaturity and Progression of Clear Cell Renal Cell Carcinoma.
BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.
DPP7 promotes fatty acid β-oxidation in tumor-associated macrophages and determines immunosuppressive microenvironment in colorectal cancer.
Targeting PDPN enhances antitumor T-cell activity by disrupting β-catenin-mediated PD-L1 expression in melanoma.
Enhancing the tumoricidal efficacy of the nanobubbles-mediated PD-L1 inhibition and immunogenic cell death in mice.
CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway.
Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB.
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism.
Naringenin: A potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma.
Traditional medicine Bazi Bushen potentiates immunosurveillance of senescent liver cancer cells via cGAS-STING signaling activation in macrophages.
OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in ccRCC.
m(6)A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma.
DB75 targets PRMT1 to suppress liver metastasis and synergizes with PD-L1 blockade for enhanced therapeutic efficacy.
Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.
Novel anti-LAG-3 antibody LBL-007 with anti-PD-1 blockade enhances antitumor immunity by promoting T cell-induced apoptosis.
Munc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes.
A Novel Self-Regulated, Non-Directional Magnetic Thermos-Brachytherapy (125)I Seed Enhances Anticancer Efficacy by Rescuing Immune Escape.
Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages.
Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1.
A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice.
Targeting PERP promotes anti-tumor immunity in HNSCC by regulating tumor immune microenvironment and metabolic homeostasis.
Osteopontin protects from ovalbumin-induced asthma by preserving the microbiome and the intestinal barrier function.
Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC.
Prognostic Value of TBC1D1 and Its Relationship With the Tumor Microenvironment in Pancreatic Cancer: A Study Based on Single-Cell Sequencing.
TBB inhibits CK2/PD-L1/EGFR pathway-mediated tumor progression.
PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17/β-catenin in nasopharyngeal carcinoma.
Hypoxia and lipid metabolism related genes drive proliferation migration and immune infiltration mechanisms in colorectal cancer subtyping.
Engineering a nano-drug delivery system to regulate m6A modification and enhance immunotherapy in gastric cancer.
MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1.
Mild Photothermal Bimetallic Mesoporous Nanozyme Triggers Immunogenic Cell Death and Immune Contexture Remodeling for Precision Hepatocellular Carcinoma Treatment.
KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8(+) T cells in colorectal cancer.
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles.
CAF-derived exosomes drive the FGF4/SHH feedback loop by encapsulating GREM1 in non-small cell lung cancer.
Inulin and hyaluronic acid-based oral liposome for enhanced photo-chemotherapy against orthotopic colon cancer and its reversal effects on tumor hypoxia and intestinal microbiota.
Chronological Effects of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
NCAPH promotes glucose metabolism reprogramming and cell stemness in ovarian cancer cells through the MEK/ERK/PD-L1 pathway.
Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment.
Probiotic-facilitated cytokine-induced killer cells suppress peritoneal carcinomatosis and liver metastasis in colorectal cancer cells.
Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation.
IGFBP5, as a Prognostic Indicator Promotes Tumor Progression and Correlates with Immune Microenvironment in Glioma.
Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.
Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.
N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer.
Long-term outcome and antitumor immune activation response in prostate cancer treated with low-dose-rate brachytherapy.
Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.
lncRNA MIAT promotes luminal B breast cancer cell proliferation, migration, and invasion in vitro.
Icaritin-curcumol activates CD8(+) T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.
RGD targeted magnetic ferrite nanoparticles enhance antitumor immunotherapeutic efficacy by activating STING signaling pathway.
Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.
DEAD-box helicase 1 inhibited CD8(+) T cell antitumor activity by inducing PD-L1 expression in hepatocellular carcinoma.
GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
The recruitment of CD8(+) T cells through YBX1 stabilization abrogates tumor intrinsic oncogenic role of MIR155HG in lung adenocarcinoma.
Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.
An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.
Bioinformatics Analysis Identifies PLA2G7 as a Key Antigen-Presenting Prognostic Related Gene Promoting Hepatocellular Carcinoma through the STAT1/PD-L1 Axis.
The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma.
MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Clinical significance, molecular characterization, and immune microenvironment analysis of coagulation-related genes in clear cell renal cell carcinoma.
A pan-cancer analysis of prognostic significance and immunological role of lysosomal-associated membrane protein 3.
Proton-Gradient-Driven Porphyrin-Based Liposome Remote-Loaded with Imiquimod as In Situ Nanoadjuvants for Synergistically Augmented Tumor Photoimmunotherapy.
Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
Inflammation-Driven Nanohitchhiker Enhances Postoperative Immunotherapy by Alleviating Prostaglandin E2-Mediated Immunosuppression.
TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation.
Bortezomib induces cell apoptosis and increases the efficacy of αPD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1.
S100A9 Induces Macrophage M2 Polarization and Immunomodulatory Role in the Lesion Site After Spinal Cord Injury in Rats.
E2F1-EP300 co-activator complex potentiates immune escape in nasopharyngeal carcinoma through the mediation of MELK.
GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.
Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.
Ginger inhibits the invasion of ovarian cancer cells SKOV3 through CLDN7, CLDN11 and CD274 m6A methylation modifications.
Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.
Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor.
Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration.
Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
LRPPRC facilitates tumor progression and immune evasion through upregulation of m(6)A modification of PD-L1 mRNA in hepatocellular carcinoma.
A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients.
Discovery of CDK signature and CDK5 as potential biomarkers for predicting prognosis and immunotherapeutic response in gastric cancer peritoneal metastases.
Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas.
Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling.
FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma.
Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway.
SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance.
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells.
Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.
ZNF480 influences the prognosis, pathogenesis, and immune microenvironment in patients with lower-grade glioma.
Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53(flox/+)LSL-Kras(G12D/+)Pdx-1-Cre murine models.
Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation.
E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.
Relationship between the expression of PD-L1 and (18)F-FDG uptake in pancreatic ductal adenocarcinoma.
m(6)A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.
Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation.
Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.
The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.
Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma.
Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade.
BMSCs improve TNBS-induced colitis in rats by inducing Treg differentiation by expressing PD-L1.
MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN.
Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients.
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Comprehensive analysis of N(6)-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer.
Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment.
Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy.
Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.
IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.
Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions.
Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer.
Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.
Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.
All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer.
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
He Y, Qian Y, Zheng Z, Zhou Y, Li C, Wu Q, Ren M
Human mutation 2026;2026:8861747
Human mutation 2026;2026:8861747
Globulol from Alpinia oxyphylla Miq. Enhances the pharmacological effects of anti-PD-1 drugs in combination by reducing PD-L1 expression in hepatocellular carcinoma.
Wang Z, Zhong Y, Hu J, Xie P, Zhao Y, Jiang C, Lu L, Zhou M, Xu J
Frontiers in pharmacology 2026;17:1728692
Frontiers in pharmacology 2026;17:1728692
Targeting CPS1 attenuates lung cancer metastasis by regulating EMT through an epigenetic mechanism.
Ding Y, Tian Y, Li M, Fu Y, Wang T, Du X, Wang M, Dong L, Gao F, Liu B, Lu Y, Zhang C, Mao L, Jiang J, Li L, Liao L, Li K
Theranostics 2026;16(4):1740-1761
Theranostics 2026;16(4):1740-1761
Targeting the ANXA2-CD63-exosomal PD-L1 axis in hepatocellular carcinoma: A novel mechanism of immune evasion and its implications for precision immunotherapy.
Zhang J, Gu Y, Zhao F, Chen Y, Xia Y, Gao D, Yuan Q, Bai X
Neoplasia (New York, N.Y.) 2026 Mar;73:101280
Neoplasia (New York, N.Y.) 2026 Mar;73:101280
Precision targeted cancer-associated fibroblast nano-regulator enhanced chemo-immunotherapy for triple-negative breast cancer.
Xian P, Zou L, Zhang J, Pan X, Song Y, Nan Y, Pu Q, Liu H, Green D, Ni S, Hu K
Biomaterials 2026 Mar;326:123679
Biomaterials 2026 Mar;326:123679
Tudor domain-containing protein 9-targeting siRNA nanoparticles alleviate Pseudomonas aeruginosa lung injury in preclinical models by promoting neutrophil cuproptosis.
Zhang W, Li H, Jia H, Xuan W, Ding L, Tan Z, Wu Q, Zhao M, Wu X
Nature communications 2026 Mar 6;17(1)
Nature communications 2026 Mar 6;17(1)
Kukoamine B Inhibits EMT in Lung Adenocarcinoma Cells by Regulating Intracellular PD-L1-Mediated p65 Nuclear Translocation.
Hou C, Chen J, Zhang L, Huang Q, Xu J, Zhang R, He Y
Biology 2026 Mar 6;15(5)
Biology 2026 Mar 6;15(5)
Engineered Bacteria-Driven Biohybrid Microrobots Potentiate IL-2 Immunotherapy by Evoking Pyroptosis.
Li P, Li Q, Ding L, Peng S, Wei H, Chen T, Xiong Y, Tang BZ, Huang X
ACS nano 2026 Mar 24;20(11):9407-9427
ACS nano 2026 Mar 24;20(11):9407-9427
Pyroptosis-Inducing Engineered Microparticles for Cancer Immunotherapy.
Hao T, Deng Z, Liu Y, Liu L, Deng D, Yang M, Geng Y, Sun Y, Yue B, Lovell JF, Liu Y, Lu L, Jin H
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Mar 18;:e74886
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Mar 18;:e74886
Integrin β4 drives immune evasion and therapeutic resistance to PD-1 blockade in bladder cancer via MEK/ERK signaling.
Lin P, Xing Z, Hong Y, Xu H, Shao S, Luo L, Zhao Y, Jin X, Li Y
The Journal of biological chemistry 2026 Jan;302(1):110941
The Journal of biological chemistry 2026 Jan;302(1):110941
Isoimperatorin inhibits cell proliferation and induces apoptosis via regulating PI3K/AKT pathway in acute lymphoblastic leukemia.
Xiao J, Wang Y
Molecular immunology 2026 Jan;189:181-191
Molecular immunology 2026 Jan;189:181-191
The active compound quercetin from Polygonum cuspidatum targets COL3A1 to enhance CD8⁺ T cell cytotoxicity in gastric cancer.
Wei Y, Guo H, Hu W, Xiao Y, Zhang J, Cao J, Shen C, Wu Z, Yin L, Gao Y
Mutation research 2026 Jan-Jun;832:111937
Mutation research 2026 Jan-Jun;832:111937
Venlafaxine suppressed PD-L1 expression through oxidative stress and improved anti-tumour immune responses in melanoma mice.
Mo M, Liang L, Li K, Ren W, Wei Y, Lei M, Fan A, Guo P, Guo S, Zhang Y, Jia H, Zhao T
Journal of drug targeting 2026 Jan 20;:1-10
Journal of drug targeting 2026 Jan 20;:1-10
Anti-Protein-Adsorption Nano-Proteolysis Targeting Chimeras as a Potent Platform for Efficient Programmed Cell Death Ligand 1 Degradation.
Lu X, Song S, Qiu F, Zhang H, Shi J, Wang B
ACS nano 2026 Feb 24;20(7):6110-6124
ACS nano 2026 Feb 24;20(7):6110-6124
An effective tumor-inhibiting siRNA delivery platform.
Leng Q, Mixson AJ
Biochemical and biophysical research communications 2026 Apr 2;807:153430
Biochemical and biophysical research communications 2026 Apr 2;807:153430
Sunitinib induces immunogenic cell death through eIF2α phosphorylation to potentiate immunotherapy in HCC.
Gu Y, Mai H, Huang P, Yuan H, Sun M, Gao H, Shang C, Ou Y, Liu T, Huang X, Tan J
iScience 2026 Apr 17;29(4):115378
iScience 2026 Apr 17;29(4):115378
H3K27ac-induced IFITM3 promotes progression of TNBC and resistance to anti-PD-1/PD-L1 therapy via the TNF-α/NF-κB/PD-L1 axis.
Li G, Fu B, Wang X, Lin H, Chen X, Zhang J
Biochimica et biophysica acta. Molecular basis of disease 2026 Apr 1;1872(6):168238
Biochimica et biophysica acta. Molecular basis of disease 2026 Apr 1;1872(6):168238
Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer.
Cheng C, Shi C, Wu S, Wu W, Li J, Gao S, Han M, Wang Y, Zhang X, Liu Y
Oncology research 2025;33(7):1633-1648
Oncology research 2025;33(7):1633-1648
Interferon Regulatory Factor 4 Recruits Immature B Cells to Signal Tertiary Lymphoid Structure Immaturity and Progression of Clear Cell Renal Cell Carcinoma.
Zhou S, Ye S, Chen L, Ge Q, Lu J, Anwaier A, Tian X, Wang Z, Zhu S, Chang K, Yang J, Li T, Zhang H, Ye D, Xiang J, Xu W
International journal of biological sciences 2025;21(9):3827-3851
International journal of biological sciences 2025;21(9):3827-3851
BRD7 Inhibited Immune Escape in Nasopharyngeal Carcinoma via Inhibiting PD-L1 Expression.
Guo Y, Lu J, Li X, Yan S, Zhou J, Tian Z, Liu Y, Li N, Zhou Q, Li X, Shi L, Jiang S, Li M, Zhou X, Huang D, Zeng Z, Fan S, Xiong W, Zhou M, Li G, Zhang W
International journal of biological sciences 2025;21(5):1914-1931
International journal of biological sciences 2025;21(5):1914-1931
DPP7 promotes fatty acid β-oxidation in tumor-associated macrophages and determines immunosuppressive microenvironment in colorectal cancer.
Chang J, Niu Y, Zhou S, Zhu W, Zhang Z, Xiu H, Shang K, Feng Q, Wei Y
International journal of biological sciences 2025;21(14):6305-6325
International journal of biological sciences 2025;21(14):6305-6325
Targeting PDPN enhances antitumor T-cell activity by disrupting β-catenin-mediated PD-L1 expression in melanoma.
Feng C, Liu Y, Zhong X, Wei Z, Cui H, Yi J
Frontiers in immunology 2025;16:1692864
Frontiers in immunology 2025;16:1692864
Enhancing the tumoricidal efficacy of the nanobubbles-mediated PD-L1 inhibition and immunogenic cell death in mice.
Liu Y, Han J, Liu C, Chen Y, Yang S, Ma Y, Zhou C, Liu R, Hu Y, Zhao Y
Frontiers in immunology 2025;16:1672324
Frontiers in immunology 2025;16:1672324
CRTC1 enhances PD-L1-mediated tumor immunosuppression in non-small cell lung cancer via the Notch1/Akt signaling pathway.
Feng X, Shi Y, Yuan F, Hu Y, Tang X, Zhang W, Gan J, Sun L, Cao L
Frontiers in immunology 2025;16:1658679
Frontiers in immunology 2025;16:1658679
Pan-Cancer Analysis of the Prognostic and Immunotherapeutic Value of PDGFB.
Bai Y, Wang X, Wang B
ImmunoTargets and therapy 2025;14:35-49
ImmunoTargets and therapy 2025;14:35-49
Stromal Stiffness-Regulated IGF2BP2 in Pancreatic Cancer Drives Immune Evasion via Sphingomyelin Metabolism.
Tang R, Zhang Z, Liu X, Liao Y, Chen Y, Xiao M, Li Y, Zhou C, Tan Z, Zhang C, Chen C, Rong Z, Liu Y, Li P, Du Q, He Q, Lei Y, Wu Z, Lu S, Xu J, Wang W, Shi S, Yu X
Gastroenterology 2025 Sep;169(4):615-631.e32
Gastroenterology 2025 Sep;169(4):615-631.e32
Naringenin: A potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma.
Wu W, Qiu X, Ye X, Zhang Z, Xu S, Yao X, Du Y, Wu G, Zhang R, Zhu J
Journal of pharmaceutical analysis 2025 Sep;15(9):101254
Journal of pharmaceutical analysis 2025 Sep;15(9):101254
Traditional medicine Bazi Bushen potentiates immunosurveillance of senescent liver cancer cells via cGAS-STING signaling activation in macrophages.
Xing F, Lv H, Xiang W, Wang L, Zong Q, Lv G, Liu C, Feng Q, Wang H, Yang W
Cancer letters 2025 Sep 1;627:217544
Cancer letters 2025 Sep 1;627:217544
OTUD1 downregulates PD-L1 expression by deubiquitinating STAT3 and promotes the immune response in ccRCC.
Liang H, Liu X, Guo W, Xiong W, Ren D, Liu W
Cellular oncology (Dordrecht, Netherlands) 2025 Oct;48(5):1349-1361
Cellular oncology (Dordrecht, Netherlands) 2025 Oct;48(5):1349-1361
m(6)A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma.
Tian F, Huang J, Fan W, Li X, Zhan Y, Zhu K, Wang X, Hong X, Wang X, Ren J, Xing Y, Cai L
Cancer communications (London, England) 2025 Oct;45(10):1285-1308
Cancer communications (London, England) 2025 Oct;45(10):1285-1308
DB75 targets PRMT1 to suppress liver metastasis and synergizes with PD-L1 blockade for enhanced therapeutic efficacy.
Sun S, Hu H, Sun P, Gao Y, Huang Y, Gong X, Chen L
International immunopharmacology 2025 Oct 30;164:115327
International immunopharmacology 2025 Oct 30;164:115327
Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.
Bu F, Ding G, Yang L, Wu Y, Xu C, Bai L, Chen R, Sun L, Qiu X, Yu P, Meng J, Fan M, Xie Y, Min L
Cancer letters 2025 Oct 28;631:217929
Cancer letters 2025 Oct 28;631:217929
Novel anti-LAG-3 antibody LBL-007 with anti-PD-1 blockade enhances antitumor immunity by promoting T cell-induced apoptosis.
Qin K, Zhou H, Yu X, Liu J, Wu C, Zhang C, Zhou L
Scientific reports 2025 Oct 27;15(1):37515
Scientific reports 2025 Oct 27;15(1):37515
Munc13-4 mediates tumor immune evasion by regulating the sorting and secretion of PD-L1 via exosomes.
Liu C, Liu D, Zheng X, Guan J, Zhou X, Zhang H, Wang S, Li Q, Lu G, He J, Ma C
Nature communications 2025 Oct 13;16(1):9080
Nature communications 2025 Oct 13;16(1):9080
A Novel Self-Regulated, Non-Directional Magnetic Thermos-Brachytherapy (125)I Seed Enhances Anticancer Efficacy by Rescuing Immune Escape.
Xu B, Wu YM, Cheng YF, Dong L, Ding SW, Chen SR, Chen BD, Yang RP, Zhang WH, Wang YJ, Mao WP, Shi F, Jin ZC, Chen JJ, Qiao EQ, Wang YQ, Li JZ, Zeng P, Wu CW, Zhang W, Xie JB, Lu J, Teng GJ
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Nov;12(43):e08091
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Nov;12(43):e08091
Formosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages.
Dai YW, Wu ZX, Cheng Y, Wu HD, Chen JW, Lv LX, Wang ZQ, Li HF, Yan CZ, Bao JX, Liu CH, Dai XX
Breast cancer research and treatment 2025 May;211(1):71-89
Breast cancer research and treatment 2025 May;211(1):71-89
Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1.
Ke ZB, Chen JY, Xue YT, Lin B, Huang Q, Huang XY, Chen DN, Chen SH, Ye XJ, Zheng QS, Wei Y, Xue XY, Xu N
Cell death & disease 2025 May 23;16(1):413
Cell death & disease 2025 May 23;16(1):413
A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice.
Liu Y, Xie Y, Chen Y, Duan J, Bao C, Wang J, Feng H, Wang M, Ren Y, Li P, Luo Q, Xu J, Jiang M, Men Y, Wu Y, Li J, Wang G, Lu W
Nature communications 2025 Mar 24;16(1):2854
Nature communications 2025 Mar 24;16(1):2854
Targeting PERP promotes anti-tumor immunity in HNSCC by regulating tumor immune microenvironment and metabolic homeostasis.
Wang X, Tian Y, Wu X, Zhu Y, Chen H, Wang Z, Liu Z, Tan J, Pan Z, Cao J, Li Z, Zhang X, Shi Z, Wang J, Liu T
Molecular cancer 2025 Jun 7;24(1):168
Molecular cancer 2025 Jun 7;24(1):168
Osteopontin protects from ovalbumin-induced asthma by preserving the microbiome and the intestinal barrier function.
Huang J, Qiao H, Li Q, Zhang Y, Zhang C, Su H, Sun X
mSystems 2025 Jun 17;10(6):e0038925
mSystems 2025 Jun 17;10(6):e0038925
Lipidomics reveals biomarkers of the efficacy of first-line ICI therapy combined with chemotherapy in NSCLC.
Yu J, Xu H, Xiong F, Liu X, Lingfei M, Gao H, Li Y
Journal of translational medicine 2025 Jun 10;23(1):638
Journal of translational medicine 2025 Jun 10;23(1):638
Prognostic Value of TBC1D1 and Its Relationship With the Tumor Microenvironment in Pancreatic Cancer: A Study Based on Single-Cell Sequencing.
Yang L, Yan D, Yu J, Deng D, Ma L, Yu R, Wei S, Yu J, Lan C, Yi P
FASEB bioAdvances 2025 Jul;7(7):e70034
FASEB bioAdvances 2025 Jul;7(7):e70034
TBB inhibits CK2/PD-L1/EGFR pathway-mediated tumor progression.
Che S, Zhang Y, Xu H, Shi J, Hou Y
European journal of pharmacology 2025 Jul 15;999:177689
European journal of pharmacology 2025 Jul 15;999:177689
PLUNC downregulates the expression of PD-L1 by inhibiting the interaction of DDX17/β-catenin in nasopharyngeal carcinoma.
Feng R, Guo Y, Chen M, Tian Z, Liu Y, Jiang S, Zhou J, Liu Q, Li X, Xiong W, Shi L, Fan S, Li G, Zhang W
Journal of pathology and translational medicine 2025 Jan;59(1):68-83
Journal of pathology and translational medicine 2025 Jan;59(1):68-83
Hypoxia and lipid metabolism related genes drive proliferation migration and immune infiltration mechanisms in colorectal cancer subtyping.
Huang S, Wang H, Cao J, Pang Q
Scientific reports 2025 Jan 18;15(1):2394
Scientific reports 2025 Jan 18;15(1):2394
Engineering a nano-drug delivery system to regulate m6A modification and enhance immunotherapy in gastric cancer.
Li Z, Zhang X, Liu C, Wu Y, Wen Y, Zheng R, Xu C, Tian J, Peng Q, Zheng X, Wang J, Yan Q, Wei L, Ma J
Acta biomaterialia 2025 Jan 1;191:412-427
Acta biomaterialia 2025 Jan 1;191:412-427
MFGE8 induces anti-PD-1 therapy resistance by promoting extracellular vesicle sorting of PD-L1.
Wang W, Chen J, Wang S, Sun X, Yang J, Yu P, Hu G, Wang J, Zhang J, Qiao S, Wang J, Zhang G, He Y, Feng H, Cai Z
Cell reports. Medicine 2025 Feb 18;6(2):101922
Cell reports. Medicine 2025 Feb 18;6(2):101922
Mild Photothermal Bimetallic Mesoporous Nanozyme Triggers Immunogenic Cell Death and Immune Contexture Remodeling for Precision Hepatocellular Carcinoma Treatment.
Huang Y, Ding L, Cao Y, Feng Q, Li Y, Wang J, Cai Z, Xin F, Wang P, Liu J
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Dec;12(46):e12578
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2025 Dec;12(46):e12578
KIAA1429 impairs anti-tumor immunity via regulation of PD-L1 and CD8(+) T cells in colorectal cancer.
Du Y, Liu Y, Wang M, Wang Y, Lin M
Scientific reports 2025 Dec 4;15(1):43619
Scientific reports 2025 Dec 4;15(1):43619
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles.
Miao G, Shang Z, Wang X, Zhang J, Xu M, He P, Zhong Q, Zhao X, Tan G, Wang X
Nature cancer 2025 Aug;6(8):1438-1457
Nature cancer 2025 Aug;6(8):1438-1457
CAF-derived exosomes drive the FGF4/SHH feedback loop by encapsulating GREM1 in non-small cell lung cancer.
Wu X, Chen W, Fang T, Chen Z, Fang S, Zhou C
Molecular medicine (Cambridge, Mass.) 2025 Aug 23;31(1):281
Molecular medicine (Cambridge, Mass.) 2025 Aug 23;31(1):281
Inulin and hyaluronic acid-based oral liposome for enhanced photo-chemotherapy against orthotopic colon cancer and its reversal effects on tumor hypoxia and intestinal microbiota.
Wang N, Hu J, Jin L, Wang S, Zeng B, Liu Y, Jin A, Piao J, Chen L, Huang W, Gao Z, Wang Y, Cui W, Jin M
International journal of biological macromolecules 2025 Apr;304(Pt 2):140996
International journal of biological macromolecules 2025 Apr;304(Pt 2):140996
Chronological Effects of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Guo X, Qin L, Wang X, Geng Q, Li D, Lu Y, Jiang H
Immunology 2025 Apr;174(4):402-410
Immunology 2025 Apr;174(4):402-410
NCAPH promotes glucose metabolism reprogramming and cell stemness in ovarian cancer cells through the MEK/ERK/PD-L1 pathway.
Qi Y, Wang A, Chen S, Chen W
Journal of ovarian research 2025 Apr 21;18(1):81
Journal of ovarian research 2025 Apr 21;18(1):81
Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment.
Zhang F, Zhou K, Yuan W, Sun K
Nutrition and cancer 2024;76(1):63-79
Nutrition and cancer 2024;76(1):63-79
Probiotic-facilitated cytokine-induced killer cells suppress peritoneal carcinomatosis and liver metastasis in colorectal cancer cells.
Chen HH, Luo CW, Chen YL, Chiang JY, Huang CR, Wang YT, Chen CH, Guo J, Yip HK
International journal of biological sciences 2024;20(15):6162-6180
International journal of biological sciences 2024;20(15):6162-6180
Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation.
Wang X, Bai Y, Wang B
Journal of inflammation research 2024;17:1805-1820
Journal of inflammation research 2024;17:1805-1820
IGFBP5, as a Prognostic Indicator Promotes Tumor Progression and Correlates with Immune Microenvironment in Glioma.
Lin J, Huang G, Zeng Q, Zhang R, Lin Y, Li Y, Huang B, Pan H
Journal of Cancer 2024;15(1):232-250
Journal of Cancer 2024;15(1):232-250
Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P, Wang S, Wan H, Huang Y, Yin K, Sun K, Jin H, Wang Z
Frontiers in immunology 2024;15:1258475
Frontiers in immunology 2024;15:1258475
EPDR1 promotes PD-L1 expression and tumor immune evasion by inhibiting TRIM21-dependent ubiquitylation of IkappaB kinase-β.
Qian X, Cai J, Zhang Y, Shen S, Wang M, Liu S, Meng X, Zhang J, Ye Z, Qiu S, Zhong X, Gao P
The EMBO journal 2024 Oct;43(19):4248-4273
The EMBO journal 2024 Oct;43(19):4248-4273
Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.
Liang Y, He S, Liu Q, Liu T, Tan Y, Peng T, Huang C, Lu X, Zheng S
Biochimica et biophysica acta. Molecular cell research 2024 Oct;1871(7):119781
Biochimica et biophysica acta. Molecular cell research 2024 Oct;1871(7):119781
N-terminal acetylation of transcription factor LIP induces immune therapy resistance via suppression of PD-L1 expression in non-small cell lung cancer.
He X, Liu Y, Gao X, Tang F, Tian Y, Gong S, Shen J, Wang A, Sun L, Wei W, Weng L
Journal for immunotherapy of cancer 2024 Nov 29;12(11)
Journal for immunotherapy of cancer 2024 Nov 29;12(11)
Long-term outcome and antitumor immune activation response in prostate cancer treated with low-dose-rate brachytherapy.
Wang Z, Wang L, Zhang Q, Xu Y, Zhang C
Medicine 2024 Nov 22;103(47):e40574
Medicine 2024 Nov 22;103(47):e40574
Adipose stem cell exosomes, stimulated by pro-inflammatory factors, enhance immune evasion in triple-negative breast cancer by modulating the HDAC6/STAT3/PD-L1 pathway through the transporter UCHL1.
Zhu Q, Zhang K, Cao Y, Hu Y
Cancer cell international 2024 Nov 20;24(1):385
Cancer cell international 2024 Nov 20;24(1):385
lncRNA MIAT promotes luminal B breast cancer cell proliferation, migration, and invasion in vitro.
Mi J, Zhang H, Jiang X, Yi Y, Cao W, Song C, Yuan C
Journal of applied genetics 2024 May;65(2):309-319
Journal of applied genetics 2024 May;65(2):309-319
Icaritin-curcumol activates CD8(+) T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.
Xu W, Li Y, Liu L, Xie J, Hu Z, Kuang S, Fu X, Li B, Sun T, Zhu C, He Q, Sheng W
Journal of experimental & clinical cancer research : CR 2024 May 23;43(1):149
Journal of experimental & clinical cancer research : CR 2024 May 23;43(1):149
RGD targeted magnetic ferrite nanoparticles enhance antitumor immunotherapeutic efficacy by activating STING signaling pathway.
Shi G, Liu X, Du Y, Tian J
iScience 2024 May 17;27(5):109062
iScience 2024 May 17;27(5):109062
Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.
Fan Z, Zhou J, Shu Q, Dong Y, Li Y, Zhang T, Bai G, Yu H, Lu F, Li J, Zhao X
Biosensors & bioelectronics 2024 May 1;251:116104
Biosensors & bioelectronics 2024 May 1;251:116104
DEAD-box helicase 1 inhibited CD8(+) T cell antitumor activity by inducing PD-L1 expression in hepatocellular carcinoma.
Liu J, Yang T, Luo Y, Ma Z, Yu Z, Zhang L, Liu G, Wen J, Lu G, Zhang G, Zhao Y, Luo W, Li Y, Yang N, Zhou J, Lu Y, Chen S, Zeng X
Cancer science 2024 Mar;115(3):763-776
Cancer science 2024 Mar;115(3):763-776
GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.
Khan B, Chen M, Wang H, Khan A, Hussain S, Shi J, Yang L, Hou Y
European journal of pharmacology 2024 Jun 5;972:176565
European journal of pharmacology 2024 Jun 5;972:176565
Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
Nie H, Yu Y, Wang F, Huang X, Wang H, Wang J, Tao M, Ning Y, Zhou J, Zhao Q, Xu F, Fang J
Cancer immunology, immunotherapy : CII 2024 Jun 4;73(8):156
Cancer immunology, immunotherapy : CII 2024 Jun 4;73(8):156
The recruitment of CD8(+) T cells through YBX1 stabilization abrogates tumor intrinsic oncogenic role of MIR155HG in lung adenocarcinoma.
Li R, Zhang Y, Wang A, Feng Y, Zhang T, Wang H, Chen Y, Yu X, Song X, Ding H, Xu L, Dong G, Jiang F
Cell death discovery 2024 Jul 23;10(1):334
Cell death discovery 2024 Jul 23;10(1):334
Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.
Zhang J, Xin Y, Ling X, Liang H, Zhang L, Fang C, Ma J
Human cell 2024 Jan;37(1):245-257
Human cell 2024 Jan;37(1):245-257
An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.
Li CY, Chou TF, Lo YL
International journal of biological macromolecules 2024 Jan;254(Pt 2):127905
International journal of biological macromolecules 2024 Jan;254(Pt 2):127905
Bioinformatics Analysis Identifies PLA2G7 as a Key Antigen-Presenting Prognostic Related Gene Promoting Hepatocellular Carcinoma through the STAT1/PD-L1 Axis.
Guo S, Yang Q
Frontiers in bioscience (Landmark edition) 2024 Jan 23;29(1):39
Frontiers in bioscience (Landmark edition) 2024 Jan 23;29(1):39
The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma.
Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P, Liu K, Zhang H, Zhang N, Li S, Zhang C
Heliyon 2024 Jan 15;10(1):e23915
Heliyon 2024 Jan 15;10(1):e23915
MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.
Cheng B, Lai Y, Huang H, Peng S, Tang C, Chen J, Luo T, Wu J, He H, Wang Q, Huang H
Environmental toxicology 2024 Feb;39(2):927-941
Environmental toxicology 2024 Feb;39(2):927-941
The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Zhu C, Du Y, Huai Q, Fang N, Xu W, Yang J, Li X, Zhang Y, Zhang X, Dai H, Li X, Wang H, Dai Y
Reproductive sciences (Thousand Oaks, Calif.) 2024 Feb;31(2):532-549
Reproductive sciences (Thousand Oaks, Calif.) 2024 Feb;31(2):532-549
Clinical significance, molecular characterization, and immune microenvironment analysis of coagulation-related genes in clear cell renal cell carcinoma.
Chen W, Zhao X, Lu Y, Wang H, Wang X, Wang Y, Liang C, Jia Z, Ma W
Cancer innovation 2024 Feb;3(1):e105
Cancer innovation 2024 Feb;3(1):e105
A pan-cancer analysis of prognostic significance and immunological role of lysosomal-associated membrane protein 3.
Feng X, Gao L, Shen X, Li M, Wang X, Hao Y, Chen J, Zhai Y, Zou B, Yao S, Guo Y, Zhang L
Journal of cellular and molecular medicine 2024 Feb;28(3):e18088
Journal of cellular and molecular medicine 2024 Feb;28(3):e18088
Proton-Gradient-Driven Porphyrin-Based Liposome Remote-Loaded with Imiquimod as In Situ Nanoadjuvants for Synergistically Augmented Tumor Photoimmunotherapy.
Liu D, Fu L, Gong L, Li S, Li K, Liu K, Yang D
ACS applied materials & interfaces 2024 Feb 21;16(7):8403-8416
ACS applied materials & interfaces 2024 Feb 21;16(7):8403-8416
Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.
Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M, Zhang H, Tian S, Zheng G, Lu D, Hu J, Guo M, Cai M, Geng X, Zhang Y, Xia J, Zhang X, Li A, Liu S, Zhang W
Cell reports. Medicine 2024 Feb 20;5(2):101357
Cell reports. Medicine 2024 Feb 20;5(2):101357
Inflammation-Driven Nanohitchhiker Enhances Postoperative Immunotherapy by Alleviating Prostaglandin E2-Mediated Immunosuppression.
Liu Y, He J, Li M, Ren K, Zhao Z
ACS applied materials & interfaces 2024 Feb 14;16(6):6879-6893
ACS applied materials & interfaces 2024 Feb 14;16(6):6879-6893
TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L, Qin N, Wan W, Song S, Hua S, Jiang C, Li N, Huang L, Gao X
American journal of physiology. Cell physiology 2024 Feb 1;326(2):C362-C381
American journal of physiology. Cell physiology 2024 Feb 1;326(2):C362-C381
Dual impacts of serine/glycine-free diet in enhancing antitumor immunity and promoting evasion via PD-L1 lactylation.
Tong H, Jiang Z, Song L, Tan K, Yin X, He C, Huang J, Li X, Jing X, Yun H, Li G, Zhao Y, Kang Q, Wei Y, Li R, Long Z, Yin J, Luo Q, Liang X, Wan Y, Zheng A, Lin N, Zhang T, Xu J, Yang X, Jiang Y, Li Y, Xiang Y, Zhang Y, Feng L, Lei Z, Shi H, Ma X
Cell metabolism 2024 Dec 3;36(12):2493-2510.e9
Cell metabolism 2024 Dec 3;36(12):2493-2510.e9
Bortezomib induces cell apoptosis and increases the efficacy of αPD-1 in BCR::ABL T315I mutation CML by targeting UBE2Q1.
Jiang F, Liu W, Zhou Y, Lin S, Zhang Q, Zhang W, Xue Y, Li C, Gao A, Shao M, Liao S, Ma T, Yu X
International immunopharmacology 2024 Dec 25;143(Pt 2):113311
International immunopharmacology 2024 Dec 25;143(Pt 2):113311
S100A9 Induces Macrophage M2 Polarization and Immunomodulatory Role in the Lesion Site After Spinal Cord Injury in Rats.
Lv J, Wang Z, Wang B, Deng C, Wang W, Sun L
Molecular neurobiology 2024 Aug;61(8):5525-5540
Molecular neurobiology 2024 Aug;61(8):5525-5540
E2F1-EP300 co-activator complex potentiates immune escape in nasopharyngeal carcinoma through the mediation of MELK.
Wang Q, Yu Q, Liu Y
Histology and histopathology 2024 Apr;39(4):511-523
Histology and histopathology 2024 Apr;39(4):511-523
GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.
Huang S, Liu J, Hu J, Hou Y, Hu M, Zhang B, Luo H, Fu S, Chen Y, Liu X, Chen Z, Wang L
Journal of cellular and molecular medicine 2024 Apr;28(8):e18290
Journal of cellular and molecular medicine 2024 Apr;28(8):e18290
Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.
Xin Q, Wang D, Wang S, Zhang L, Liang Q, Yan X, Fan K, Jiang B
Advanced healthcare materials 2024 Apr;13(11):e2303623
Advanced healthcare materials 2024 Apr;13(11):e2303623
Ginger inhibits the invasion of ovarian cancer cells SKOV3 through CLDN7, CLDN11 and CD274 m6A methylation modifications.
Zhang X, Zhang H, Zhu L, Xia L
BMC complementary medicine and therapies 2024 Apr 4;24(1):145
BMC complementary medicine and therapies 2024 Apr 4;24(1):145
Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.
Cui Z, Li C, Liu W, Sun M, Deng S, Cao J, Yang H, Chen P
Cell death & disease 2024 Apr 15;15(4):267
Cell death & disease 2024 Apr 15;15(4):267
Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor.
Yang H, Ma L, Deng W, Fu B, Nie J, Liu X
Frontiers in immunology 2023;14:1301945
Frontiers in immunology 2023;14:1301945
Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration.
Zhang C, Huang G, Yang J, Jiang Y, Huang R, Ye Z, Huang Y, Hu H, Xi X
Frontiers in immunology 2023;14:1197011
Frontiers in immunology 2023;14:1197011
Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Chen H, Yang W, Ji Z
Frontiers in immunology 2023;14:1171420
Frontiers in immunology 2023;14:1171420
LRPPRC facilitates tumor progression and immune evasion through upregulation of m(6)A modification of PD-L1 mRNA in hepatocellular carcinoma.
Wang H, Tang A, Cui Y, Gong H, Li H
Frontiers in immunology 2023;14:1144774
Frontiers in immunology 2023;14:1144774
A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients.
Zhou Y, Yin W, Kuang Y, Wu Z, Huang H, Liu W, Jiang X, Ren C
Frontiers in immunology 2023;14:1138363
Frontiers in immunology 2023;14:1138363
Discovery of CDK signature and CDK5 as potential biomarkers for predicting prognosis and immunotherapeutic response in gastric cancer peritoneal metastases.
Sun Y, Chen Y, Cai Y, Wang X, Chen Q, Fang S, Lian M, Lv C, Weng J, Huang R, Zhuang W, Xue F, Cai L, Lin Y, Wang Q
American journal of cancer research 2023;13(9):4087-4100
American journal of cancer research 2023;13(9):4087-4100
Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas.
Xu D, Cao M, Wang B, Bi X, Zhang H, Wu D, Zhang C, Xu J, Xu Z, Zheng D, Chen L, Li P, Wang H, Liu Y, Jiang H, Li K
Theranostics 2023;13(5):1490-1505
Theranostics 2023;13(5):1490-1505
Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling.
Yu C, Zhang X, Wang M, Xu G, Zhao S, Feng Y, Pan C, Yang W, Zhou J, Shang L, Ma Y
Frontiers in oncology 2023;13:1198118
Frontiers in oncology 2023;13:1198118
FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
Wang D, Wu S, He J, Sun L, Zhu H, Zhang Y, Liu S, Duan X, Wang Y, Xu T
Journal of experimental & clinical cancer research : CR 2023 Sep 1;42(1):222
Journal of experimental & clinical cancer research : CR 2023 Sep 1;42(1):222
Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma.
Liao C, Li M, Chen X, Tang C, Quan J, Bode AM, Cao Y, Luo X
Journal of experimental & clinical cancer research : CR 2023 Oct 7;42(1):261
Journal of experimental & clinical cancer research : CR 2023 Oct 7;42(1):261
Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.
Liu Y, Wang Q, Yu S, Liu M, Han J, Sun B
Journal of medicinal chemistry 2023 Oct 12;66(19):13838-13857
Journal of medicinal chemistry 2023 Oct 12;66(19):13838-13857
Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.
Zhang L, Zhao X, Niu Y, Ma X, Yuan W, Ma J
Journal of extracellular vesicles 2023 Nov;12(11):e12379
Journal of extracellular vesicles 2023 Nov;12(11):e12379
Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway.
Deng D, Xu F, Ma L, Zhang T, Wang Y, Huang S, Zhao W, Chen X
Molecular neurobiology 2023 May;60(5):2922-2936
Molecular neurobiology 2023 May;60(5):2922-2936
SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance.
Wu Y, Wang Z, Li S, Chen X, Zhou S
Experimental and therapeutic medicine 2023 May;25(5):195
Experimental and therapeutic medicine 2023 May;25(5):195
Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.
Wang T, Wu L, Wang S, Shi X, Liu H, Deng W
Chinese journal of natural medicines 2023 May;21(5):333-345
Chinese journal of natural medicines 2023 May;21(5):333-345
PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells.
Yan L, Sun Y, Guo J, Jia R
International journal of molecular sciences 2023 May 3;24(9)
International journal of molecular sciences 2023 May 3;24(9)
Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.
Qiu J, Wu X, Luo Y, Yao Y, Zhang X, Pan B, Wang X, Tang N
Gene 2023 Mar 10;856:147132
Gene 2023 Mar 10;856:147132
ZNF480 influences the prognosis, pathogenesis, and immune microenvironment in patients with lower-grade glioma.
Zhu Q, Liu Z, Cheng X, Liang W, Wang H, Li P, Zhang J, Chen Y, Gao Y, Qian R
Heliyon 2023 Jul;9(7):e18185
Heliyon 2023 Jul;9(7):e18185
Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.
Wen J, Yang S, Yan G, Lei J, Liu X, Zhang N, Zhang J, Deng H, Wu L, Li Y
Experimental cell research 2023 Jul 15;428(2):113651
Experimental cell research 2023 Jul 15;428(2):113651
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53(flox/+)LSL-Kras(G12D/+)Pdx-1-Cre murine models.
Qiu J, Feng M, Yang G, Cao Z, Liu Y, You L, Zhang T
Cancer letters 2023 Feb 1;554:216020
Cancer letters 2023 Feb 1;554:216020
Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation.
Xiang W, Lv H, Xing F, Sun X, Ma Y, Wu L, Lv G, Zong Q, Wang L, Wu Z, Feng Q, Yang W, Wang H
Science advances 2023 Dec 8;9(49):eadi2465
Science advances 2023 Dec 8;9(49):eadi2465
E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.
Tang F, Lu C, He X, Lin W, Xie B, Gao X, Peng Y, Yang D, Sun L, Weng L
Cell reports 2023 Dec 26;42(12):113477
Cell reports 2023 Dec 26;42(12):113477
Relationship between the expression of PD-L1 and (18)F-FDG uptake in pancreatic ductal adenocarcinoma.
Li J, Chen R, Chen Y, Xia Q, Zhou X, Xia Q, Wang C, Wan L, Bao H, Huang G, Liu J
British journal of cancer 2023 Aug;129(3):541-550
British journal of cancer 2023 Aug;129(3):541-550
m(6)A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.
Yu Y, Meng LL, Chen XY, Fan HN, Chen M, Zhang J, Zhu JS
Cellular signalling 2023 Aug;108:110699
Cellular signalling 2023 Aug;108:110699
Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation.
Qin H, Chen Y, Wang Z, Li N, Sun Q, Lin Y, Qiu W, Qin Y, Chen L, Chen H, Li Y, Shi J, Nie G, Zhao R
Nature communications 2023 Aug 24;14(1):5178
Nature communications 2023 Aug 24;14(1):5178
Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.
Peng Z, Lu C, Shi G, Yin L, Liang X, Song G, Tian J, Du Y
European journal of nuclear medicine and molecular imaging 2023 Apr;50(5):1291-1305
European journal of nuclear medicine and molecular imaging 2023 Apr;50(5):1291-1305
The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.
Hu X, Zhang Y, Yu H, Zhao Y, Sun X, Li Q, Wang Y
Frontiers in immunology 2022;13:1012173
Frontiers in immunology 2022;13:1012173
Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma.
Zhu L, Liu J, Qiu M, Chen J, Liang Q, Peng G, Zou Z
Biomaterials 2022 Sep;288:121711
Biomaterials 2022 Sep;288:121711
Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.
Ren Y, Pan F, Kan X, Wang J, Han P, Yan J, Li L, Sun P, Liu CY, Bao Q, Yang L, Zheng C
Molecular pharmaceutics 2022 Oct 3;19(10):3664-3672
Molecular pharmaceutics 2022 Oct 3;19(10):3664-3672
Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade.
Jiang Y, Yang Y, Hu Y, Yang R, Huang J, Liu Y, Wu Y, Li S, Ma C, Humphries F, Wang B, Wang X, Hu Z, Yang S
Cell reports 2022 Oct 25;41(4):111553
Cell reports 2022 Oct 25;41(4):111553
BMSCs improve TNBS-induced colitis in rats by inducing Treg differentiation by expressing PD-L1.
Gao F, Cui D, Zuo D, Shou Z, Yang J, Yu T, Liu Y, Chu S, Zhu F, Wei C
Biotechnology letters 2022 Nov;44(11):1263-1275
Biotechnology letters 2022 Nov;44(11):1263-1275
MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN.
Gong J, Shen Y, Jiang F, Wang Y, Chu L, Sun J, Shen P, Chen M
Oncology letters 2022 May;23(5):148
Oncology letters 2022 May;23(5):148
Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients.
Yu H, Lv W, Tan Y, He X, Wu Y, Wu M, Zhang Q
Journal of translational medicine 2022 Jul 21;20(1):328
Journal of translational medicine 2022 Jul 21;20(1):328
A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W, Ren D, Xiong W, Jin X, Zhu L
Journal of experimental & clinical cancer research : CR 2022 Jan 26;41(1):38
Journal of experimental & clinical cancer research : CR 2022 Jan 26;41(1):38
Comprehensive analysis of N(6)-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer.
Cui J, Zhu Y, Liu X, Wang W, Jiang X, Xia Y, Zhou G, Chen S, Shi B
Cancer cell international 2022 Feb 11;22(1):72
Cancer cell international 2022 Feb 11;22(1):72
Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment.
Liu Y, Guo Q, Yang H, Zhang XW, Feng N, Wang JK, Liu TT, Zeng KW, Tu PF
ACS central science 2022 Aug 24;8(8):1102-1115
ACS central science 2022 Aug 24;8(8):1102-1115
Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy.
Yao Y, Chen H, Tan N
Acta pharmaceutica Sinica. B 2022 Apr;12(4):2103-2119
Acta pharmaceutica Sinica. B 2022 Apr;12(4):2103-2119
Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.
Mudd AM, Gu T, Munagala R, Jeyabalan J, Fraig M, Egilmez NK, Gupta RC
Oncoscience 2021;8:120-133
Oncoscience 2021;8:120-133
IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.
Yuan W, Deng D, Li H, Hu X, Shang X, Hou X, Jiang H, He H
OncoTargets and therapy 2021;14:3051-3062
OncoTargets and therapy 2021;14:3051-3062
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.
Zhang L, Wang X, Li Y, Han J, Gao X, Li S, Wang F
Clinical and translational medicine 2021 Sep;11(9):e464
Clinical and translational medicine 2021 Sep;11(9):e464
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.
Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Cañete-Portillo S, Chaux A, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Bonasoni MP, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Athanazio D, Gandhi J, Cavazza A, Santandrea G, Tafuni A, Zanelli M
Cells 2021 Nov 14;10(11)
Cells 2021 Nov 14;10(11)
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X, Zhang M, Wei A, Yin F, Wang Y, Hu K, Jiang J
Nanoscale 2021 May 21;13(19):8998-9008
Nanoscale 2021 May 21;13(19):8998-9008
A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.
Long Y, Wang Z, Fan J, Yuan L, Tong C, Zhao Y, Liu B
Journal of materials chemistry. B 2021 May 12;9(18):3838-3855
Journal of materials chemistry. B 2021 May 12;9(18):3838-3855
Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions.
Yu L, Feng R, Zhu L, Hao Q, Chu J, Gu Y, Luo Y, Zhang Z, Chen G, Chen H
Science advances 2020 Nov;6(47)
Science advances 2020 Nov;6(47)
Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer.
Zheng S, Zou Y, Liang JY, Xiao W, Yang A, Meng T, Lu S, Luo Z, Xie X
Molecular oncology 2020 Nov;14(11):2814-2833
Molecular oncology 2020 Nov;14(11):2814-2833
Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.
Ju X, Zhang H, Zhou Z, Chen M, Wang Q
Experimental cell research 2020 Nov 15;396(2):112315
Experimental cell research 2020 Nov 15;396(2):112315
New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X
European journal of nuclear medicine and molecular imaging 2020 May;47(5):1127-1136
European journal of nuclear medicine and molecular imaging 2020 May;47(5):1127-1136
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.
Otsuka K, Mitsuhashi A, Goto H, Hanibuchi M, Koyama K, Ogawa H, Ogino H, Saijo A, Kozai H, Yoneda H, Tobiume M, Kishuku M, Ishizawa K, Nishioka Y
Lung cancer (Amsterdam, Netherlands) 2020 Aug;146:86-96
Lung cancer (Amsterdam, Netherlands) 2020 Aug;146:86-96
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Lenouvel D, González-Moles MÁ, Talbaoui A, Ramos-García P, González-Ruiz L, Ruiz-Ávila I, Gil-Montoya JA
Oral diseases 2020 Apr;26(3):511-526
Oral diseases 2020 Apr;26(3):511-526
Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.
Wang Q, Xiang Q, Yu L, Hu T, Chen Y, Wang J, Nie X, Cheng J
Frontiers in oncology 2019;9:1545
Frontiers in oncology 2019;9:1545
Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.
Liu K, Du S, Gao P, Zheng J
Journal of Cancer 2019;10(18):4196-4207
Journal of Cancer 2019;10(18):4196-4207
All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.
Chen XJ, He MJ, Zhou G
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2019 Oct;48(9):832-839
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2019 Oct;48(9):832-839
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer.
Cao D, Qi Z, Pang Y, Li H, Xie H, Wu J, Huang Y, Zhu Y, Shen Y, Zhu Y, Dai B, Hu X, Ye D, Wang Z
Cancer research 2019 May 15;79(10):2604-2618
Cancer research 2019 May 15;79(10):2604-2618
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith HG, Mansfield D, Roulstone V, Kyula-Currie JN, McLaughlin M, Patel RR, Bergerhoff KF, Paget JT, Dillon MT, Khan A, Melcher A, Thway K, Harrington KJ, Hayes AJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Jun 1;25(11):3443-3454
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Jun 1;25(11):3443-3454
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Li J, Yu T, Yan M, Zhang X, Liao L, Zhu M, Lin H, Pan H, Yao M
Experimental cell research 2019 Jan 15;374(2):304-314
Experimental cell research 2019 Jan 15;374(2):304-314
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Yuan W, Deng D, Jiang H, Tu C, Shang X, He H, Niu R, Dong J
Cancer immunology, immunotherapy : CII 2019 Feb;68(2):257-268
Cancer immunology, immunotherapy : CII 2019 Feb;68(2):257-268
PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Gao H, Zhang J, Ren X
Bioscience reports 2019 Dec 20;39(12)
Bioscience reports 2019 Dec 20;39(12)
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX
Oral oncology 2018 Nov;86:81-90
Oral oncology 2018 Nov;86:81-90
Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
Imanishi N, Hirai A, Yoneda K, Shimajiri S, Kuwata T, Tashima Y, Takeuchi M, Iwai Y, Ichiki Y, Tanaka F
Journal of surgical oncology 2018 Jun;117(7):1563-1569
Journal of surgical oncology 2018 Jun;117(7):1563-1569
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y
Lung cancer (Amsterdam, Netherlands) 2017 Feb;104:7-15
Lung cancer (Amsterdam, Netherlands) 2017 Feb;104:7-15
Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
Chen TC, Wu CT, Wang CP, Hsu WL, Yang TL, Lou PJ, Ko JY, Chang YL
Oral oncology 2015 Nov;51(11):1004-1010
Oral oncology 2015 Nov;51(11):1004-1010
No comments: Submit comment
No validations: Submit validation data